A Solid Foundation Laid Amidst Transformation
Optima Health’s maiden full-year results since its AIM listing tell a compelling story of strategic groundwork paying dividends. While headline revenue dipped 5% to £105m (from £110.9m in FY24), this masks significant underlying progress. Adjusting for the pre-listing loss of one major client and reduced scope with another – well-flagged events – the group actually returned to organic growth. More importantly, Optima has aggressively repositioned itself: slashing net debt (excluding leases) by 94% to a nimble £2.2m, securing a transformative £210m MoD contract, and executing three earnings-accretive acquisitions. This isn’t treading water; it’s building a launchpad.
Financials: Resilience and Recalibration
Peeling back the layers reveals a robust operational core. Adjusted EBITDA held remarkably steady at £17.6m (FY24: £18.0m), with the margin actually improving 40 basis points to 16.7%. This demonstrates tight cost control amidst integration efforts and inflationary pressures (more on those later). Statutory figures show the clean-up operation: operating profit swung to £3.2m from a £0.7m loss, absorbing £2.8m in one-off demerger and listing costs.
Key Financial Snapshot
- Revenue: £105.0m (FY24: £110.9m) – Underlying growth achieved post-adjustments.
- Adjusted EBITDA: £17.6m (Margin: 16.7%)
- Statutory Operating Profit: £3.2m (vs FY24 loss of £0.7m)
- Net Debt (ex. leases): £2.2m (FY24: £34.0m) – A dramatic deleveraging.
- New Business Wins: £27.2m (FY24: £7.3m) – Pipeline momentum is strong.
The balance sheet transformation is arguably the star. Moving from £34m net debt to just £2.2m (excluding leases) provides immense strategic flexibility. With a £20m RCF (only £17m drawn) and a net debt/EBITDA ratio of a miniscule 0.16x, Optima is armed for its buy-and-build strategy.
Strategic Thrust: Contracts, Acquisitions & Innovation
FY25 wasn’t about standing still. Optima delivered on multiple strategic pillars:
1. The MoD Blockbuster
The jewel in the crown is the £210m, seven-year (potentially £290m over ten years) contract with the UK Ministry of Defence, secured in partnership with Serco. Providing medical assessments for Armed Forces recruitment, this isn’t just revenue – it’s a prestigious anchor client validating Optima’s clinical scale and operational capability. Mobilisation is underway, with service revenues expected in about 18 months. This single contract significantly boosts the group’s visibility and backlog.
2. Acquisition Engine Firing
Optima didn’t just talk M&A; it delivered, integrating three strategic buys since listing:
- BHSF Occupational Health (Jan ’25): Added £8m revenue, ~60 clinicians, and expanded UK footprint. Profitable from day one.
- Cognate Health (Apr ’25 – Post-period): The crucial first step internationally, adding ~€7m revenue and entry to the Republic of Ireland with 30 clinics and 35 physicians.
- Care first (May ’25 – Post-period): Priory Group’s EAP business, bolting on £3.7m revenue and strengthening mental health offerings.
Critically, all are expected to be EBITDA accretive within their first full year – disciplined capital deployment.
3. Tech Breakthrough: DART in the NHS
Beyond traditional OH, Optima’s proprietary Digital Assessment Routing Tool (DART) landed its first NHS licence contract with Mersey & West Lancashire Teaching Hospitals. Four further NHS trusts under the GIRFT initiative quickly followed. This demonstrates the potential to monetise tech IP in adjacent markets, opening a promising new revenue stream.
Market Context: Riding Powerful Tailwinds
Optima operates in a structurally supportive market. The UK corporate occupational health sector is valued at £1.2bn, forecast to hit £1.4bn by 2028. Key drivers are undeniable:
- £150bn annual economic cost of ill-health absence (7% of UK GDP).
- Skyrocketing NHS waiting lists (c. 7.4m) pushing employers towards private solutions.
- 2.8 million people economically inactive due to ill health (up 25% since 2020).
- Board-level focus on wellbeing (78% of employers tackling stress).
- Fragmented market ripe for consolidation (Optima holds ~10% share of outsourced segment).
Optima’s strategy – organic growth in core UK OH, disciplined M&A, tech-enabled expansion into adjacent markets (like MoD, NHS), and geographical reach (Ireland) – directly capitalises on these dynamics.
Navigating Headwinds and the FY26 Outlook
It wasn’t all smooth sailing. CEO Jonathan Thomas openly acknowledged challenges:
- Cost Pressures: Employers’ National Insurance increases and Real Living Wage inflation hit margins. Mitigation plans are in motion.
- New Business Conversion: Slower than hoped in H2 FY25 (ex-MoD), though actions are underway to accelerate this.
Despite this, the tone is unequivocally confident. The MoD ramp-up, full integration of acquisitions (minimising margin dilution), the NHS DART pipeline, and a supportive market underpin the board’s expectation of growth in FY26. The successful appeal against the DWP (remedies pending) is another potential upside.
Verdict: Building Momentum for the Next Phase
Optima Health’s FY25 results are less about spectacular top-line fireworks and more about strategic heavy lifting executed effectively. They’ve navigated a complex demerger and listing, integrated legacy acquisitions, dramatically strengthened the balance sheet, landed a transformative MoD contract, made savvy international and capability-enhancing acquisitions, and seen their tech gain traction in the NHS. While near-term cost headwinds require management, the foundations for sustainable, diversified growth are firmly in place. With a clear strategy, a strengthened platform, and a £27m+ new business win pipeline, Optima looks well-positioned to shift gears in FY26 and beyond. As Thomas succinctly put it: the ambition is to “lead the transformation of business to business workplace healthcare.” FY25 suggests they’re building the tools to do just that.
